GLP-1 Cost Comparison 2026: Every Option From $25 to $1,349 Per Month

The cheapest way to get GLP-1 medications depends on your insurance, your diagnosis, and which medication you choose. Here's the complete breakdown so you can find your actual number.

GLP-1 medications cost anywhere from $25 to $1,349 per month in 2026, depending on which drug you choose, whether you have insurance, and which pharmacy channel you use. That 54-fold spread is wide enough to determine whether treatment is realistic for you — so the details matter more than any single headline number.

This guide compares every GLP-1 pricing tier available right now: brand-name options from Novo Nordisk and Eli Lilly, manufacturer cash-pay programs, insurance pathways, and compounded alternatives from telehealth providers.

The Complete GLP-1 Pricing Landscape

There are six primary pricing pathways for GLP-1 medications in 2026. Each one has different eligibility requirements and trade-offs worth understanding before you commit.

Cheapest Way to Get GLP-1 by Situation

Your cheapest path depends entirely on your starting point. Here's a decision framework based on what matters most: your insurance status, your diagnosis, and how much you're willing to spend.

If You Have Commercial Insurance

Check whether your plan covers Wegovy, Ozempic, Zepbound, or Mounjaro. If it does, apply for the manufacturer savings card immediately. Novo Nordisk's card brings Wegovy and Ozempic copays down to $25 per month (capped at $100/month in savings). Eli Lilly's savings card does the same for Zepbound and Mounjaro.

This is the absolute cheapest path to brand-name, FDA-approved GLP-1 treatment. The catch: your plan has to cover the medication first, and many commercial plans still exclude weight-loss drugs.

If You Don't Have Insurance (or No Coverage for Weight Loss)

You have three realistic options, ranked by cost:

1. Compounded semaglutide ($99–$300/month): The lowest entry point for most uninsured patients. Available through telehealth providers partnered with licensed 503A or 503B compounding pharmacies. Availability narrowed in 2025 after the FDA resolved the semaglutide shortage, but providers still offer compounded formulations for patients with documented medical needs.
2. NovoCare Rybelsus ($149/month): FDA-approved oral semaglutide at $149/month for 1.5 mg and 4 mg tablets through Novo Nordisk's direct cash-pay program. This price is available through at least August 2026.
3. NovoCare Wegovy ($199–$349/month): FDA-approved injectable semaglutide through Novo Nordisk's cash-pay channel. Starter doses (0.25 mg and 0.5 mg) run $199/month through June 2026, stepping up to $349/month for the standard maintenance dose range.

If You Want Tirzepatide Specifically

Tirzepatide (the dual GLP-1/GIP agonist in Mounjaro and Zepbound) has shown slightly higher weight loss in head-to-head trials versus semaglutide. If you want tirzepatide without insurance:

• Compounded tirzepatide ($149–$399/month): Available through select telehealth providers. Note that tirzepatide compounding availability has also been affected by regulatory changes.
• LillyDirect Zepbound vials ($499/month): Flat-rate pricing regardless of dose — you pay the same whether you're on 2.5 mg or 15 mg. You draw your own dose with a syringe, which requires a small learning curve.

Brand-Name vs. Compounded: The Trade-Offs

The decision between brand-name and compounded GLP-1 medications involves more than just price. Both have legitimate advantages depending on your situation.

What About Medicare and Medicaid?

Medicare Part D has traditionally excluded anti-obesity medications, which meant Medicare patients couldn't get coverage for Wegovy regardless of medical need. That's changing in 2026 — the GLP-1 Bridge Program makes Zepbound KwikPen available to eligible Medicare beneficiaries at approximately $50/month starting July 1, 2026.

Mounjaro is covered under Medicare Part D when prescribed for type 2 diabetes, making it the most accessible brand-name option for Medicare patients with diabetes.

Medicaid coverage varies dramatically by state. Some states cover Wegovy for obesity; most still don't. Check with your state Medicaid program for current formulary information.

How to Save the Most Money in 2026

Regardless of which medication you choose, these strategies can reduce your out-of-pocket costs:

Apply for manufacturer savings programs first. Both Novo Nordisk and Eli Lilly offer savings cards that can drop your copay to $25/month with commercial insurance. These programs are free to join and take minutes to set up.

Use HSA or FSA funds. All GLP-1 medications — brand-name and compounded — are eligible HSA/FSA expenses when prescribed by a licensed provider. This effectively gives you a tax discount of 20–35% depending on your tax bracket.

Compare total costs, not headline prices. A provider advertising "$99/month medication" plus a $79 membership fee plus $30 shipping is actually $208/month. Always calculate the total.

Ask about multi-month bundles. Many telehealth providers offer 3-month or 6-month bundles at lower per-month rates. If you're committed to treatment, bundles can save 15–25% versus monthly pricing.

Check patient assistance programs. Novo Nordisk's Lilly Cares and NovoCare programs offer free medication to qualifying low-income patients. Income limits apply, but the application is straightforward.

The Bottom Line on GLP-1 Costs

The cheapest way to get GLP-1 medications in 2026 depends on your specific situation. For insured patients with coverage, manufacturer savings cards at $25/month are unbeatable. For uninsured patients, compounded semaglutide from reputable telehealth providers offers the lowest entry point, while NovoCare's direct cash-pay programs provide an FDA-approved alternative at competitive prices.

The worst thing you can do is pay retail pharmacy list price. Between manufacturer programs, compounding options, and telehealth providers, there's almost certainly a pathway that makes GLP-1 treatment affordable for your budget.